Implantable Drug Eluting Devices Market Snapshot (2022 to 2029)

Global Implantable Drug Eluting Devices Market is set to experience significant growth of 6.0% CAGR from 2022 to 2029, with an estimated market value of around US$ 12.8 Billion as of 2022. As per Future Market Insights projections, contraceptive drug eluting devices products hold a substantial share of over 39.8% in 2021 within the global market.

Data Points Market Insights
Market Value 2021 US$ 12.1 Billion
Market Value 2022 US$ 12.8 Billion
Market Value 2029 US$ 19.3 Billion
CAGR 2022 to 2029 6.0%
Market Share of Top 5 Countries 76.5%

With the growth in demand for minimally-invasive procedures, implantable drug eluting devices are accumulating a rising range in terms of market penetration, which are established by key market leaders.

Similarly, start-up companies as well as majorly rooted corporations over the globe are working hard to develop novel implantable drug delivery technologies, using a wide range of knowledge available in the network which includes research institutions, universities, teaching hospitals, and companies.

Due to a massive demand for combination products such as drug eluting devices, major players in the market are adopting competitive strategies such as acquisitions, mergers, as well as collaborations for the development and augmentation of products in the market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed Till June 2022?

Particulars Details
H1, 2021 6.03%
H1, 2022 Projected 6.00%
H1, 2022 Outlook 5.90%
BPS Change - H1, 2022 (O) – H1, 2022 (P) (-) 10 ↓
BPS Change – H1, 2022 (O) – H1, 2021 (-) 13 ↓

According to Future Market Insights’ analysis, the global implantable drug eluting devices market will observe a diminished change in the Basis Point Share (BPS) by nearly 13 BPS in H1- 2022 (O) as compared with H1-2021. The attribute of non-biodegradable implants, which includes the requirement for surgical removal or the accumulation of polymer in the body after usage, has a negative impact on the total market.

Non-biodegradable implants are generally more traumatic to remove than they are to place. This is based on available clinical studies data. The comparative analysis and market growth rate of the global implantable drug eluting devices market as studied by Future Market Insights will show a negative BPS growth in the H1-2022 outlook as compared to H1-2022 projected period by 10 BPS. Furthermore, the manufacture of implants necessitates the use of huge amounts of organic solvent, which might affect drug stability and toxicity, as well as raise environmental problems.

On the contrary, numerous factors present several benefits to the overall implantable drug eluting devices market, including the adoption of compression as a manufacturing technique for implantable drugs, which refrains from the use of heat or solvents, making it a suitable method for the manufacture of implants containing heat or solvent sensitive compounds such proteins or peptides.

This is set to advance the manufacturing capacities of key producers within the global industry space.

Implantable Drug Eluting Devices Market

Sales Analysis of Implantable Drug Eluting Devices from 2014 to 2021 Vs Market Outlook for 2022 to 2029

The market value for Implantable Drug Eluting Devices holds nearly 5.8% of the overall US$ 208.0 Billion Drug Delivery Devices market in 2021.

Implantable drug eluting devices provide numerous distinctive advantages which include the exceptional prospects of site-specificity, localization, and targeted drug delivery process.

The applications of implantable drug eluting devices are indispensable when considered under the scope of cardiology, ophthalmology, birth control, opioid addiction, pain management, diabetes management, contraception, as well as cancer therapy. The targeted drug delivery systems improve the efficacy of treatment (oncology and cardiology) and assist with the reduction of side effects by preventing damage to healthy tissue.

The implantable drug eluting devices are segmented into two main types: active drug eluting devices and passive drug eluting devices.

The technologies essentially incorporated in the active drug eluting devices are electromechanical and osmotic pressure gradients. Furthermore, the passive drug eluting devices are sub-segmented into 2 types which include biodegradable implants and non-biodegradable implants, wherein, the biodegradable implants are polyester amide and Polylactic glycolic acids devised and the non-biodegradable implantable devices are made using silicon, polyethylene-vinyl acetate, and thermoplastic polyurethane.

The non-biodegradable implants possess wide-ranging applications in diabetes, contraception, hormone regulation, pain management, cancer treatment, etc. Implantable drug delivery devices commonly comprise a drug reservoir enclosed by a polymer or a mixture of a drug-polymer.

The implant, when incorporated into the desired, localized area of the body, releases the drug at a pre-calculated rate whilst the polymer degrades.

The effective drug delivery system through implantable drug eluting devices is thus set to gain traction in terms of adoption over the forecast period, owing to the specificity of the target site and the rate of drug dissolution into the localized area of therapy.

The market is expected to expand at a considerable growth rate over the next seven years at a CAGR of close to 6.0%.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Key Opportunities for Implantable Drug Eluting Devices Manufacturers?

The implantable drug eluting devices is predicted to exhibit lucrative growth over the forecast period. This growth can be associated with the rising adoption of patient-controlled devices and increasing the incidence of peripheral and coronary artery diseases. Additionally, the key market players are displaying extensive focus on clinical trials of bio-reabsorbable stents and implantable drug infusion pumps.

Therefore, the growing adoption by patients and physicians, and rising demand for minimally invasive surgeries are set to offer growth opportunities to key market players in the development of novel implantable drug-eluting devices. Furthermore, the rising incidence of cardiovascular and chronic diseases over the globe is generating growth opportunities for the global implantable drug eluting devices market.

According to the WHO, cardiovascular diseases are one of the major causes of mortality globally.

Several research and clinical studies are currently taking place for the improvement of the functioning of existing drug eluting stents and devices. Research in this area is thus focused on the evaluation and development of novel and augmented drug eluting devices, which uphold notable clinical benefits and eliminate safety concerns regarding their long-term application. The innovative efforts in research on next-generation drug eluting devices are expected to further progress procedures such as endothelialization and rapid arterial healing.

These factors are thus comprehensively set to promote the growth of the implantable drug eluting devices market throughout the forecast period.

What are the Factors Restraining Demand for Implantable Drug Eluting Devices?

The factors associated with risks associated with the limited demand and value growth of the implantable drug eluting devices include the process of product recalls, which are indispensable for public health and safety as it leads to the voluntary action of manufacturers and distributors to carry out their responsibility that presents a risk of injury or defective or gross deception of products.

Additionally, pending approvals of products by regulatory bodies may hinder the growth of injunctions which can restrain the sale of products and may remarkably divert the attention of the management and technical personnel in the market. In the event of approval pending, the company's financial condition, business, and results of operations could be adversely affected. Moreover, several implantable drug eluting devices pose a problem in terms of patient adherence, terms of discomfort upon the implants being incorporated into them.

The ongoing biodegradation of the drug-eluting stents sometimes makes it difficult to maintain the accurate dose at the end of its lifetime. There is always a risk of device failure, which may result in another surgical involvement to correct the device.

Another factor of concern includes the fact that most implants possess an inadequate loading capacity owing to their small size. This gives way to some specific potent medicines for appropriate delivery by implantable devices.

The concerns arising from bodily reaction to a foreign substance also conceive a restrictive growth in the deployment of implants in lieu of its biocompatibility and safety. These factors collectively induce restraint in the growth of the implantable drug eluting devices market, however, augmented and personalized implant designing may prove to enhance the efficacy of the implanted drug delivery process.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

What Makes the USA the Largest Market for Implantable Drug Eluting Devices?

The USA dominates the North American region with a total market share of over 94.1% in 2021 and is projected to continue experiencing high growth throughout the forecast period.

The vast majority of shares gained by the USA in the implantable drug eluting devices market are owed to the factors associated with rising disease burden, increasing geriatric population, and the developing healthcare infrastructure which offers reimbursement opportunities for new procedures.

Why is Germany Considered a Lucrative Market for Implantable Drug Eluting Devices in Europe?

Germany is set to exhibit a CAGR of over 6.2% in the European implantable drug eluting devices market during the forecast period. The lucrative growth in the region is associated with the emergence of key and established players in the country, focusing on research and innovative methodologies for drug delivery and targeted site delivery systems.

What Makes China an Emerging Market for Implantable Drug Eluting Devices?

China holds a 46.1% market revenue share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 8.7% during the forecast period. The growth of the implantable drug eluting devices market in the country is attributed to the development of novel drug delivery technologies, such as an implantable nanogenerator, which can be adopted for precise drug delivery systems. Furthermore, increasing government funding for research and development activities is set to augment the China implantable drug eluting devices market over the forecast period.

What is the Outlook for Japan Regarding Implantable Drug Eluting Devices?

In 2021, Japan held a 39.3% share in the East Asia implantable drug eluting devices market and is projected to expand at a CAGR of 8.2% from 2022 to 2029. The growth is associated with the rapid adoption of automated systems in the country, including models for site-specific and targeted drug delivery systems. These augmentations are cost-effective and reduce the error rate during clinical trials.

Category-wise Insights

Which Implantable Drug Eluting Devices Product is Driving Market Growth?

Contraceptive drug eluting devices project lucrative growth at a CAGR of 6.0% till the end of the forecast period, with a market share of around 39.8% in 2021. The growth is associated with the factor of increasing awareness in terms of female and reproductive health over the globe, and the efforts to minimize the mortality and morbidity rate associated with female reproductive health.

Which Technology is Large of Focus in the Implantable Drug Eluting Devices Market?

Passive drug eluting device technology holds a revenue share of 96.2% in 2021 and is projected to hold a share over the forecast period with the estimation being 96.6%. The segment holds the maximum revenue share due to the wide-ranging applications of passive drug eluting devices in the field of oncology, cardiology, pain management, contraception, etc.

Which Application is Large of Focus in the Implantable Drug Eluting Devices Market?

Cardiovascular applications hold a revenue share of 45.1% in 2021 and are projected to hold a share over the forecast period with the estimation being 47.3%. The segment gains traction with the rising incidence of chronic diseases and the risks associated with infectious agents among the geriatric population.

Which Implantation Type Holds a Dominant Stance in the Global Implantable Drug Eluting Devices Market?

Intravascular implantation type holds a revenue share of 44.1% in 2021 and is projected to hold a share over the forecast period with the estimation being 46.1%. The extensive ranging applications of the intravascular implants as well as the efficient patient adherence and outcomes have contributed to this method being implemented widely across several treatment indications.

Which End User Holds a Dominant Stance in the Global Implantable Drug Eluting Devices Market?

Hospitals hold a revenue share of 61.9% in 2021 and are projected to hold a share over the forecast period with the estimation being 66.0%. The process of targeted drug delivery through implantable drug eluting devices requires the aid of skilled physicians with patient data for close monitoring in the event of implant rejection or other adverse events. Thus, the hospital segment accounts for a massive share of the implantable drug eluting devices market.

Competitive Landscape

Corporate tie-ups amongst implantable drug eluting device manufacturers, acquisitions, expansion, product launches, agreements, and increasing clinical trials and research activities are the key strategies adopted by manufacturers to increase product sales in different geographies.

  • In August 2021, Medtronic plc announced that it has entered into a definitive agreement with Intersect ENT a global medical technology leader dedicated to transforming patient care, in which Medtronic will acquire all outstanding shares of Intersect ENT.
  • In March 2020, Allergan received FDA approval for DURYSTA™ (bimatoprost implant) the first and only Intracameral Biodegradable Sustained-Release implant to lower intraocular pressure in Open-Angle Glaucoma or Ocular Hypertension Patients.

Similarly, recent developments related to companies operating in the implantable drug eluting devices market have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as per Implantable Drug Eluting Devices Market Analysis

Attribute Details
Forecast Period 2022 to 2029
Historical Data Available for 2014 to 2021
Market Analysis US$ Million for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, Northern Africa, South Africa, Turkey
Key Market Segments Covered Product, Technology, Application, Implantation Type, End User, and Region
Key Companies Profiled
  • Pfizer Inc.
  • Medtronic Inc.
  • Merck & Co., In
  • Bayer AG
  • JOHNSON & JOHNSON
  • SurModics Inc.
  • AstraZeneca Plc.
  • Boston Scientific Corporation
  • Titan Pharmaceuticals, Inc.
  • BIOTRONIK, INC.
  • Abbott Laboratories
  • Allergan, Inc.
  • Bausch and Lomb, Inc.
  • Alimera Sciences
  • REVA Medical, Inc.
Pricing Available upon Request

Key Market Segments Covered in Implantable Drug Eluting Devices Industry Research

By Product:

  • Implantable Drug Infusion Pumps
  • Intraocular Drug Eluting Devices
  • Contraceptive Drug Eluting Devices
  • Buprenorphine Implant
  • Drug Eluting Stents
  • Others

By Technology:

  • Active Drug Eluting Device
  • Passive Drug Eluting Device
    • Biodegradable Implants
    • Non-Biodegradable Implants

By Application:

  • Diabetic Macular Edema
  • Birth Control/Contraception
  • Opioid Addiction
  • Cardiovascular
  • Ophthalmology
  • Oncology
  • Pain Management

By Implementation Type:

  • Intravaginal
  • Intravascular
  • Intraocular
  • Intrathecal
  • Subcutaneous
  • Intrauterine

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Optical Care Centers
  • Cardiac Surgery Centers
  • Office Based Settings
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

How much is the Implantable Drug Eluting Devices market currently worth?

The global implantable drug eluting devices market is worth US$ 12.1 Billion at present and is set to expand 1.5 X over the next seven years.

What is the sales forecast for Implantable Drug Eluting Devices through 2029?

The implantable drug eluting devices market is expected to reach US$ 19.3 Billion by the end of 2029, with sales revenue expected to register 6.0% CAGR.

What are the key trends shaping the Implantable Drug Eluting Devices industry?

Growing research collaborations and distribution of implantable drug eluting devices by key market leaders, new product launches and government initiatives are some of the key trends being witnessed in this marketplace.

Which are the top 5 countries driving demand for Implantable Drug Eluting Devices?

The USA, Germany, the United Kingdom, France, and China are expected to drive demand in the implantable drug eluting devices market.

What is the North America market outlook for Implantable Drug Eluting Devices?

North America is one of the key markets for implantable drug eluting devices, with the USA expected to account for over 95.3% of the North American market during the forecast period.

At what percentage is the demand for Implantable Drug Eluting Devices expected to register growth in Europe?

Demand for implantable drug eluting devices in Europe is expected to register a growth of 4.9% over the next seven years.

Which countries are key producers of Implantable Drug Eluting Devices products?

The USA, United Kingdom, and Germany are key producers of implantable drug eluting device products.

Which are the key exporters of Implantable Drug Eluting Devices market?

Pfizer Inc., Medtronic Inc., Merck & Co. In, Bayer AG, JOHNSON & JOHNSON, SurModics Inc., AstraZeneca Plc., Boston Scientific Corporation, Titan Pharmaceuticals, Inc., BIOTRONIK, INC., Abbott Laboratories, Allergan, Inc., Bausch and Lomb, Inc., Alimera Sciences, and REVA Medical, Inc. are the key exporters of implantable drug eluting devices market.

Table of Content

1. Executive Summary | Implantable Drug Eluting Devices Market

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusion & Exclusion/ Scope of the Report

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Development Trends

4. Key Success Factors

    4.1. New Product Launches & Regulatory Approvals

    4.2. Key Strategies Followed By Manufacturers

5. Market Context

    5.1. Product Adoption / Application Analysis

    5.2. Regulatory Scenario

    5.3. Value Chain Analysis

    5.4. Reimbursement Scenario

6. Global Market Demand Analysis 2014 to 2021 and Forecast, 2022 to 2029

    6.1. Historical Market Volume (Units) Analysis, 2014 to 2021

    6.2. Current and Future Market Volume (Units) Projections, 2021 to 2029

        6.2.1. Y-o-Y Growth Trend Analysis

7. Global Market Pricing Analysis

    7.1. Regional Pricing Analysis By Product

    7.2. Pricing Break-up

        7.2.1. Manufacturer-Level Pricing

        7.2.2. Distributor Level Pricing

    7.3. Global Average Pricing Analysis Benchmark

8. Global Market Demand (in Value or Size in US$ Million) Analysis 2014 to 2021 and Forecast, 2022 to 2029

    8.1. Historical Market Value (US$ Million) Analysis, 2014 to 2021

    8.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2029

        8.2.1. Y-o-Y Growth Trend Analysis

        8.2.2. Absolute $ Opportunity Analysis

9. Market Background

    9.1. Macro-Economic Factors

        9.1.1. Global GDP Growth Outlook

        9.1.2. Global Healthcare Outlook

        9.1.3. Per Capita Healthcare Expenditure Outlook

    9.2. Forecast Factors - Relevance & Impact

    9.3. Market Dynamics

        9.3.1. Drivers

        9.3.2. Restraints

        9.3.3. Opportunity Analysis

10. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Technology

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis By Technology, 2014 to 2021

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Technology, 2022 to 2029

        10.3.1. Active Drug Eluting Device

        10.3.2. Passive Drug Eluting Device

            10.3.2.1. Biodegradable implants

            10.3.2.2. Non-biodegradable implants

    10.4. Market Attractiveness Analysis By Technology

11. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Product

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Million) Analysis By Product, 2014 to 2021

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2022 to 2029

        11.3.1. Implantable Drug Infusion Pumps

        11.3.2. Intraocular Drug Eluting Devices

        11.3.3. Contraceptive Drug Eluting Devices

        11.3.4. Buprenorphine Implant

        11.3.5. Drug-Eluting Stents

        11.3.6. Others

    11.4. Market Attractiveness Analysis By Product

12. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Application

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Million) Analysis By Application, 2014 to 2021

    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2022 to 2029

        12.3.1. Diabetic Macular Edema

        12.3.2. Birth Control/Contraception

        12.3.3. Opioid Addiction

        12.3.4. Cardiovascular

        12.3.5. Ophthalmology

        12.3.6. Oncology

        12.3.7. Pain Management

    12.4. Market Attractiveness Analysis By Application

13. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Implantation Type

    13.1. Introduction / Key Findings

    13.2. Historical Market Size (US$ Million) Analysis By Implantation Type, 2014 to 2021

    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Implantation Type, 2022 to 2029

        13.3.1. Intravaginal

        13.3.2. Intravascular

        13.3.3. Intraocular

        13.3.4. Intrathecal

        13.3.5. Subcutaneous

        13.3.6. Intrauterine

    13.4. Market Attractiveness Analysis By Implantation Type

14. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by End User

    14.1. Introduction / Key Findings

    14.2. Historical Market Size (US$ Million) Analysis By End User, 2014 to 2021

    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2029

        14.3.1. Hospitals

        14.3.2. Ambulatory Surgical Centres

        14.3.3. Optical Care Centres

        14.3.4. Cardiac Surgery Centres

        14.3.5. Office based settings

        14.3.6. Others

    14.4. Market Attractiveness Analysis By End User

15. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Region

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Analysis By Region, 2014 to 2021

    15.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2029

        15.3.1. North America

        15.3.2. Latin America

        15.3.3. Europe

        15.3.4. Middle East and Africa (MEA)

        15.3.5. East Asia

        15.3.6. South Asia

        15.3.7. Oceania

    15.4. Market Attractiveness Analysis By Region

16. North America Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021

    16.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029

        16.3.1. By Country

            16.3.1.1. USA

            16.3.1.2. Canada

        16.3.2. By Technology

        16.3.3. By Product

        16.3.4. By Application

        16.3.5. By Implantation Type

        16.3.6. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Technology

        16.4.3. By Product

        16.4.4. By Application

        16.4.5. By Implantation Type

        16.4.6. By End User

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Latin America Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021

    17.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029

        17.3.1. By Country

            17.3.1.1. Brazil

            17.3.1.2. Mexico

            17.3.1.3. Rest of Latin America

        17.3.2. By Technology

        17.3.3. By Product

        17.3.4. By Application

        17.3.5. By Implantation Type

        17.3.6. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Technology

        17.4.3. By Product

        17.4.4. By Application

        17.4.5. By Implantation Type

        17.4.6. By End User

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. Europe Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    18.1. Introduction

    18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021

    18.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029

        18.3.1. By Country

            18.3.1.1. Germany

            18.3.1.2. Italy

            18.3.1.3. France

            18.3.1.4. United Kingdom

            18.3.1.5. Spain

            18.3.1.6. BENELUX

            18.3.1.7. Russia

            18.3.1.8. Rest of Europe

        18.3.2. By Technology

        18.3.3. By Product

        18.3.4. By Application

        18.3.5. By Implantation Type

        18.3.6. By End User

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Technology

        18.4.3. By Product

        18.4.4. By Application

        18.4.5. By Implantation Type

        18.4.6. By End User

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

19. South Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    19.1. Introduction

    19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021

    19.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029

        19.3.1. By Country

            19.3.1.1. India

            19.3.1.2. Thailand

            19.3.1.3. Indonesia

            19.3.1.4. Malaysia

            19.3.1.5. Rest of South Asia

        19.3.2. By Technology

        19.3.3. By Product

        19.3.4. By Application

        19.3.5. By Implantation Type

        19.3.6. By End User

    19.4. Market Attractiveness Analysis

        19.4.1. By Country

        19.4.2. By Technology

        19.4.3. By Product

        19.4.4. By Application

        19.4.5. By Implantation Type

        19.4.6. By End User

    19.5. Key Market Participants - Intensity Mapping

    19.6. Drivers and Restraints - Impact Analysis

20. East Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    20.1. Introduction

    20.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021

    20.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029

        20.3.1. By Country

            20.3.1.1. China

            20.3.1.2. Japan

            20.3.1.3. South Korea

        20.3.2. By Technology

        20.3.3. By Product

        20.3.4. By Application

        20.3.5. By Implantation Type

        20.3.6. By End User

    20.4. Market Attractiveness Analysis

        20.4.1. By Country

        20.4.2. By Technology

        20.4.3. By Product

        20.4.4. By Application

        20.4.5. By Implantation Type

        20.4.6. By End User

    20.5. Key Market Participants - Intensity Mapping

    20.6. Drivers and Restraints - Impact Analysis

21. Oceania Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    21.1. Introduction

    21.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021

    21.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029

        21.3.1. By Country

            21.3.1.1. Australia

            21.3.1.2. New Zealand

        21.3.2. By Technology

        21.3.3. By Product

        21.3.4. By Application

        21.3.5. By Implantation Type

        21.3.6. By End User

    21.4. Market Attractiveness Analysis

        21.4.1. By Country

        21.4.2. By Technology

        21.4.3. By Product

        21.4.4. By Application

        21.4.5. By Implantation Type

        21.4.6. By End User

    21.5. Key Market Participants - Intensity Mapping

    21.6. Drivers and Restraints - Impact Analysis

22. Middle East and Africa Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    22.1. Introduction

    22.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021

    22.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029

        22.3.1. By Country

            22.3.1.1. GCC Countries

            22.3.1.2. Turkey

            22.3.1.3. Northern Africa

            22.3.1.4. South Africa

            22.3.1.5. Rest of Middle East and Africa

        22.3.2. By Technology

        22.3.3. By Product

        22.3.4. By Application

        22.3.5. By Implantation Type

        22.3.6. By End User

    22.4. Market Attractiveness Analysis

        22.4.1. By Country

        22.4.2. By Technology

        22.4.3. By Product

        22.4.4. By Application

        22.4.5. By Implantation Type

        22.4.6. By End User

    22.5. Key Market Participants - Intensity Mapping

    22.6. Drivers and Restraints - Impact Analysis

23. Emerging Countries Market Analysis 2014 to 2021 and Forecast 2022 to 2029

    23.1. Introduction

        23.1.1. Market Value Proportion Analysis, By Key Countries

        23.1.2. Global Vs. Country Growth Comparison

    23.2. China Market Analysis

        23.2.1. Introduction

        23.2.2. Market Value Proportion Analysis by Market Taxonomy

        23.2.3. Market Value (US$ Million) Analysis and Forecast by Market Taxonomy

            23.2.3.1. By Technology

            23.2.3.2. By Product

            23.2.3.3. By Application

            23.2.3.4. By Implantation Type

            23.2.3.5. By End User

        23.2.4. China Market - Competition Landscape

    23.3. India Market Analysis

        23.3.1. Introduction

        23.3.2. Market Value Proportion Analysis by Market Taxonomy

        23.3.3. Market Value (US$ Million) Analysis and Forecast by Market Taxonomy

            23.3.3.1. By Technology

            23.3.3.2. By Product

            23.3.3.3. By Application

            23.3.3.4. By Implantation Type

            23.3.3.5. By End User

        23.3.4. India Market - Competition Landscape

    23.4. Brazil Market Analysis

        23.4.1. Introduction

        23.4.2. Market Value Proportion Analysis by Market Taxonomy

        23.4.3. Market Value (US$ Million) Analysis and Forecast by Market Taxonomy

            23.4.3.1. By Technology

            23.4.3.2. By Product

            23.4.3.3. By Application

            23.4.3.4. By Implantation Type

            23.4.3.5. By End User

        23.4.4. Brazil Market - Competition Landscape

24. Market Structure Analysis

    24.1. Market Structure Analysis by Tier of Companies

    24.2. Market Share Analysis

    24.3. Market Concentration

    24.4. Market Presence Analysis

      24.4.1. By Regional Footprint of Players

      24.4.2. Product foot print by Players

      24.4.3. Channel Foot Print by Players

25. Competition Analysis

    25.1. Competition Dashboard

    25.2. Competition Deep Dive

        25.2.1. Pfizer Inc.

            25.2.1.1. Overview

            25.2.1.2. Product Portfolio

            25.2.1.3. Profitability by Market Segment

            25.2.1.4. Sales Footprint

            25.2.1.5. Strategy Overview

                25.2.1.5.1. Marketing Strategy

                25.2.1.5.2. Product Strategy

                25.2.1.5.3. Channel Strategy

        25.2.2. Medtronic Inc.

            25.2.2.1. Overview

            25.2.2.2. Product Portfolio

            25.2.2.3. Profitability by Market Segment

            25.2.2.4. Sales Footprint

            25.2.2.5. Strategy Overview

                25.2.2.5.1. Marketing Strategy

                25.2.2.5.2. Product Strategy

                25.2.2.5.3. Channel Strategy

        25.2.3. Merck & Co., In

            25.2.3.1. Overview

            25.2.3.2. Product Portfolio

            25.2.3.3. Profitability by Market Segment

            25.2.3.4. Sales Footprint

            25.2.3.5. Strategy Overview

                25.2.3.5.1. Marketing Strategy

                25.2.3.5.2. Product Strategy

                25.2.3.5.3. Channel Strategy

        25.2.4. Bayer AG

            25.2.4.1. Overview

            25.2.4.2. Product Portfolio

            25.2.4.3. Profitability by Market Segment

            25.2.4.4. Sales Footprint

            25.2.4.5. Strategy Overview

                25.2.4.5.1. Marketing Strategy

                25.2.4.5.2. Product Strategy

                25.2.4.5.3. Channel Strategy

        25.2.5. Johnson & Johnson

            25.2.5.1. Overview

            25.2.5.2. Product Portfolio

            25.2.5.3. Profitability by Market Segment

            25.2.5.4. Sales Footprint

            25.2.5.5. Strategy Overview

                25.2.5.5.1. Marketing Strategy

                25.2.5.5.2. Product Strategy

                25.2.5.5.3. Channel Strategy

        25.2.6. SurModics Inc.

            25.2.6.1. Overview

            25.2.6.2. Product Portfolio

            25.2.6.3. Profitability by Market Segment

            25.2.6.4. Sales Footprint

            25.2.6.5. Strategy Overview

                25.2.6.5.1. Marketing Strategy

                25.2.6.5.2. Product Strategy

                25.2.6.5.3. Channel Strategy

        25.2.7. AstraZeneca Plc.

            25.2.7.1. Overview

            25.2.7.2. Product Portfolio

            25.2.7.3. Profitability by Market Segment

            25.2.7.4. Sales Footprint

            25.2.7.5. Strategy Overview

                25.2.7.5.1. Marketing Strategy

                25.2.7.5.2. Product Strategy

                25.2.7.5.3. Channel Strategy

        25.2.8. Boston Scientific Corporation

            25.2.8.1. Overview

            25.2.8.2. Product Portfolio

            25.2.8.3. Profitability by Market Segment

            25.2.8.4. Sales Footprint

            25.2.8.5. Strategy Overview

                25.2.8.5.1. Marketing Strategy

                25.2.8.5.2. Product Strategy

                25.2.8.5.3. Channel Strategy

        25.2.9. Titan Pharmaceuticals, Inc.

            25.2.9.1. Overview

            25.2.9.2. Product Portfolio

            25.2.9.3. Profitability by Market Segment

            25.2.9.4. Sales Footprint

            25.2.9.5. Strategy Overview

                25.2.9.5.1. Marketing Strategy

                25.2.9.5.2. Product Strategy

                25.2.9.5.3. Channel Strategy

        25.2.10. BIOTRONIK, INC.

            25.2.10.1. Overview

            25.2.10.2. Product Portfolio

            25.2.10.3. Profitability by Market Segment

            25.2.10.4. Sales Footprint

            25.2.10.5. Strategy Overview

                25.2.10.5.1. Marketing Strategy

                25.2.10.5.2. Product Strategy

                25.2.10.5.3. Channel Strategy

        25.2.11. Abbott Laboratories

            25.2.11.1. Overview

            25.2.11.2. Product Portfolio

            25.2.11.3. Profitability by Market Segment

            25.2.11.4. Sales Footprint

            25.2.11.5. Strategy Overview

                25.2.11.5.1. Marketing Strategy

                25.2.11.5.2. Product Strategy

                25.2.11.5.3. Channel Strategy

        25.2.12. Allergan, Inc.

            25.2.12.1. Overview

            25.2.12.2. Product Portfolio

            25.2.12.3. Profitability by Market Segment

            25.2.12.4. Sales Footprint

            25.2.12.5. Strategy Overview

                25.2.12.5.1. Marketing Strategy

                25.2.12.5.2. Product Strategy

                25.2.12.5.3. Channel Strategy

        25.2.13. Bausch and Lomb, Inc.

            25.2.13.1. Overview

            25.2.13.2. Product Portfolio

            25.2.13.3. Profitability by Market Segment

            25.2.13.4. Sales Footprint

            25.2.13.5. Strategy Overview

                25.2.13.5.1. Marketing Strategy

                25.2.13.5.2. Product Strategy

                25.2.13.5.3. Channel Strategy

        25.2.14. Alimera Sciences 

            25.2.14.1. Overview

            25.2.14.2. Product Portfolio

            25.2.14.3. Profitability by Market Segment

            25.2.14.4. Sales Footprint

            25.2.14.5. Strategy Overview

                25.2.14.5.1. Marketing Strategy

                25.2.14.5.2. Product Strategy

                25.2.14.5.3. Channel Strategy

        25.2.15. REVA Medical, Inc.

            25.2.15.1. Overview

            25.2.15.2. Product Portfolio

            25.2.15.3. Profitability by Market Segment

            25.2.15.4. Sales Footprint

            25.2.15.5. Strategy Overview

                25.2.15.5.1. Marketing Strategy

                25.2.15.5.2. Product Strategy

                25.2.15.5.3. Channel Strategy

26. Assumptions and Acronyms Used

27. Research Methodology

Recommendations

Healthcare

Microneedle Drug Delivery Systems Market

November 2020

REP-GB-2750

June 2024

345 pages

Healthcare

Injectable Drug Delivery Market

December 2021

REP-GB-393

April 2024

342 pages

Healthcare

Connected Drug Delivery Devices Market

December 2021

REP-GB-2755

July 2022

228 pages

Healthcare

Implantable Drug Eluting Devices Market

February 2022

REP-GB-10671

June 2022

326 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Implantable Drug Eluting Devices Market